<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="196711">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00530218</url>
  </required_header>
  <id_info>
    <org_study_id>98074</org_study_id>
    <secondary_id>P30CA033572</secondary_id>
    <secondary_id>CHNMC-98074</secondary_id>
    <secondary_id>CDR0000564546</secondary_id>
    <nct_id>NCT00530218</nct_id>
  </id_info>
  <brief_title>Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant</brief_title>
  <official_title>Phase II Study of Intravenous Ganciclovir Followed by Oral Ganciclovir in the Treatment of Reactivation of CMV Following Bone Marrow Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Antiviral drugs, such as ganciclovir, act against viruses. Giving ganciclovir by
      infusion and then by mouth may be effective treatment for cytomegalovirus that has become
      active after donor bone marrow transplant.

      PURPOSE: This phase II trial is studying how well giving ganciclovir by infusion and by
      mouth works in treating patients with cytomegalovirus after donor bone marrow transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  To determine the feasibility of using oral ganciclovir (GCV) following induction with
           intravenous GCV in the setting of cytomegalovirus (CMV) reactivation after bone marrow
           transplantation.

        -  To evaluate the clearance of CMV as measured by quantitative plasma polymerase chain
           reaction (PCR) using this schema of treatment.

        -  To establish the feasibility of measuring steady state GCV blood levels in patients on
           oral GCV.

        -  To correlate GCV pharmacokinetic data with clinical outcome of these patients.

        -  To explore the feasibility of a CMV management guideline that incorporates PCR results
           in clinical decision making.

      OUTLINE: Blood cultures for cytomegalovirus (CMV) are obtained periodically after the
      planned bone marrow transplantation (BMT). Patients showing reactivation of CMV receive
      induction ganciclovir (GCV) IV twice a day on days 1-7. Patients then receive maintenance
      oral GCV three times a day for 5 weeks in the absence of disease progression or unacceptable
      toxicity.

      Patients undergo blood collection periodically during study for pharmacokinetic studies.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1999</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient compliance with an oral ganciclovir (GCV) regimen following induction with IV GCV as measured by a self-recorded patient diary and number of adverse events</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Observation of cytomegalovirus (CMV) in blood as measured by either blood culture or polymerase chain reaction (PCR) during the course of antiviral treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of CMV-associated disease that occurs during or after treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of CMV blood infection that occurs after treatment and during the period to day 180</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GCV blood levels</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of the GCV pharmacokinetic data with clinical outcome</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Practical ability to utilize PCR-based decisions</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Diseases</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ganciclovir</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Undergoing allogeneic transplantation, including unrelated donor bone marrow
             transplantation (BMT) and/or allogeneic donor leukocyte infusion, for any indication

          -  Patients or their donors must have had a positive pre-BMT cytomegalovirus (CMV)
             antibody titer as measured by enzyme-linked immunosorbent assay (ELISA)

          -  No signs or symptoms of documented CMV infection, including any positive CMV culture
             from any site and/or any suspected or documented CMV-associated clinical syndrome, at
             the time of study entry

          -  No history of symptomatic CMV-associated clinical syndrome

        PATIENT CHARACTERISTICS:

          -  Able to comply with study requirements

          -  No history of hypersensitivity to ganciclovir or acyclovir

        PRIOR CONCURRENT THERAPY:

          -  No other concurrent investigational antiviral agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricardo T. Spielberger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Comprehensive Cancer Center</affiliation>
  </overall_official>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 27, 2014</lastchanged_date>
  <firstreceived_date>September 13, 2007</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>atypical chronic myeloid leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>chronic eosinophilic leukemia</keyword>
  <keyword>chronic idiopathic myelofibrosis</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>chronic neutrophilic leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>myelodysplastic/myeloproliferative disease, unclassifiable</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II mantle cell lymphoma</keyword>
  <keyword>noncontiguous stage II marginal zone lymphoma</keyword>
  <keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>refractory hairy cell leukemia</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ganciclovir</mesh_term>
    <mesh_term>Ganciclovir triphosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
